Delcath Systems Inc

DCTH.US
Healthcare · Medical Devices
11.55
-0.39 (-3.27%)
USD · NASDAQ

Company Information

Company Name
Delcath Systems Inc
Sector
Healthcare
Industry
Medical Devices
Exchange
NASDAQ
ISIN: US24661P8077
CIK: 0000872912
CUSIP: 24661P807
Currency: USD
Full Time Employees: 156
Phone: 212 489 2100
Fiscal Year End: December
IPO Date: May 29, 2018
Description:

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Address:

566 Queensbury Avenue, Queensbury, NY, United States, 12804

People

Directors & Officers

Name Title Year Born
Mr. Gerard J. Michel MBA, MS CEO & Director 1963
Dr. Martha S. Rook Ph.D. Chief Operating Officer 1971
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. Chief Medical Officer 1967
Ms. Sandra Pennell CPA Chief Financial Officer 1979
Mr. David Hoffman J.D. General Counsel, Corporate Secretary & Chief Compliance Officer 1970
Dr. Johnny John M.D. Senior Vice President of Clinical Operations & Medical Affairs 1965
Mr. Kevin Muir Chief Commercial Officer NA
Dr. Michael Brunner M.D. Senior Vice President of Interventional Oncology NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Nov 11, 2025 Gerard J Michel N/A Purchase 11.50K $8.53 $98.10K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Rosalind Advisors, Inc. 3.30M Mar 31, 2026 9.56% $12.31 0.00%
BlackRock Inc 1.78M Mar 31, 2026 5.17% $0.00 -2.23%
Vanguard Group Inc 1.67M Dec 31, 2025 4.84% $0.00 0.90%
Vanguard Capital Management, LLC 1.33M Mar 31, 2026 3.85% $0.00 0.00%
Propel Bio Management LLC 979.70K Mar 31, 2026 2.84% $5.77 123.42%
Geode Capital Management, LLC 692.03K Mar 31, 2026 2.00% $0.00 1.35%
State Street Corp 664.43K Mar 31, 2026 1.92% $0.00 9.28%
Private Wealth Advisors, LLC 591.52K Mar 31, 2026 1.71% $1.54 103.64%
Millennium Management LLC 588.06K Mar 31, 2026 1.70% $0.00 138.62%
Divisadero Street Capital Management, LP 499.80K Mar 31, 2026 1.45% $0.19 0.00%
Ikarian Capital, LLC 431.25K Mar 31, 2026 1.25% $0.32 0.00%
Morgan Stanley - Brokerage Accounts 385.52K Mar 31, 2026 1.12% $0.00 24.95%
The Goldman Sachs Group Inc 289.13K Mar 31, 2026 0.84% $0.00 -50.80%
Simplify Asset Management Inc. 264.77K Jun 30, 2026 0.77% $0.05 1.40%
Northern Trust Corp 251.86K Mar 31, 2026 0.73% $0.00 4.68%
ADAR1 Capital Management LLC 224.39K Mar 31, 2026 0.65% $0.12 0.00%
Kennedy Capital Management Inc 207.92K Mar 31, 2026 0.60% $0.04 2.55%
Lane Generational LLC 205.09K Mar 31, 2026 0.59% $1.52 3.74%
Vanguard Fiduciary Trust Co 201.82K Mar 31, 2026 0.58% $0.00 0.00%
Royce & Associates, LP 195.00K Mar 31, 2026 0.56% $0.02 25.81%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 889.41K 2.58% ▼ 9.52% Jun 30, 2026
2 iShares Russell 2000 ETF 761.72K 2.21% ▲ 0.60% Jun 30, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 304.81K 0.88% ▼ 2.23% Jun 30, 2026
4 Fidelity Small Cap Index 297.85K 0.86% ▲ 0.82% Apr 30, 2026
5 Simplify Propel Opportunities ETF 261.13K 0.76% ▲ 0.00% Jun 30, 2026
6 CREF Total Global Stock Account R3 241.85K 0.70% ▲ 50.08% May 31, 2026
7 State St Russell Sm/Mid Cp® Indx SL Cl I 236.48K 0.69% ▲ 0.00% Jun 30, 2026
8 iShares Russell 2000 Value ETF 228.23K 0.66% ▼ 0.69% Jun 30, 2026
9 Russell 2000 Index Non-Lendable Fund 197.17K 0.57% ▼ 0.22% Jun 30, 2026
10 Russell 2000 Equity Index Fund B 197.17K 0.57% ▼ 0.22% Jun 30, 2026

Financial Highlights

Market Cap: $412.19M
EBITDA: $-1.32M
P/E Ratio: $1.19K
PEG Ratio: $1.60
Book Value: $3.27
Earnings/Share: $0.01
Profit Margin: 0.62%
Operating Margin: -6.55%
ROA (TTM): -0.95%
ROE (TTM): 0.58%
Revenue (TTM): $90.44M
Revenue/Share (TTM): $2.50
Earnings Growth (YOY): -66.70%
Revenue Growth (YOY): 26.30%

Valuation Metrics

Enterprise Value: $324.49M
Trailing P/E: 1.19K
Forward P/E: 25.77

Shares Statistics

Shares Outstanding: 34.52M
Shares Float: 28.60M
% Insiders: 812.60%
% Institutions: 4,906.20%
Short % Float: 8.50%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$85.23M
Cost of Goods Sold
adjust
$-11.80M
Gross Profit
subtotal
$73.43M
SG&A
adjust
$-43.53M
R&D
adjust
$-29.25M
Operating Income
subtotal
$660.00K
Other / Non-Operating Items
adjust
$2.04M
Net Income
subtotal
$2.70M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about DCTH.US!